Eric Padron

15.1k total citations
331 papers, 4.1k citations indexed

About

Eric Padron is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Eric Padron has authored 331 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 278 papers in Hematology, 172 papers in Genetics and 64 papers in Molecular Biology. Recurrent topics in Eric Padron's work include Acute Myeloid Leukemia Research (260 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (120 papers) and Chronic Myeloid Leukemia Treatments (65 papers). Eric Padron is often cited by papers focused on Acute Myeloid Leukemia Research (260 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (120 papers) and Chronic Myeloid Leukemia Treatments (65 papers). Eric Padron collaborates with scholars based in United States, France and Italy. Eric Padron's co-authors include Rami S. Komrokji, Alan F. List, Jeffrey E. Lancet, David A. Sallman, Najla Al Ali, Najla H. Al Ali, Mavis Agbandje‐McKenna, Robert McKenna, Kendra Sweet and Nicholas Muzyczka and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eric Padron

296 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Padron United States	31	2.8k	1.7k	1.6k	620	477	331	4.1k
Katherine R. Calvo United States	39	2.4k 0.8×	1.4k 0.8×	1.7k 1.1×	709 1.1×	843 1.8×	141	5.1k
Clayton A. Smith United States	35	2.9k 1.0×	1.1k 0.7×	2.7k 1.7×	356 0.6×	1.1k 2.4×	129	5.5k
Austin Kulasekararaj United Kingdom	35	3.3k 1.2×	1.5k 0.9×	880 0.6×	329 0.5×	579 1.2×	207	5.1k
Ulrike Bacher Germany	39	4.1k 1.5×	2.1k 1.2×	1.8k 1.2×	252 0.4×	1.1k 2.3×	281	5.7k
Shigeo Horiike Japan	31	2.1k 0.8×	933 0.6×	1.6k 1.0×	321 0.5×	935 2.0×	165	4.1k
Chihiro Shimazaki Japan	33	2.4k 0.8×	813 0.5×	1.5k 0.9×	298 0.5×	1.2k 2.6×	213	4.0k
Norio Asou Japan	34	2.9k 1.0×	836 0.5×	2.4k 1.5×	225 0.4×	783 1.6×	180	4.8k
Stephen T. Oh United States	27	1.6k 0.6×	1.6k 1.0×	1.4k 0.9×	211 0.3×	909 1.9×	151	3.7k
Dale L. Bixby United States	27	1.6k 0.6×	864 0.5×	1.1k 0.7×	127 0.2×	756 1.6×	135	3.2k
Mike Griffiths United Kingdom	33	1.1k 0.4×	419 0.3×	920 0.6×	355 0.6×	332 0.7×	73	2.8k

Countries citing papers authored by Eric Padron

Since Specialization

Citations

This map shows the geographic impact of Eric Padron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Padron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Padron more than expected).

Fields of papers citing papers by Eric Padron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Padron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Padron. The network helps show where Eric Padron may publish in the future.

Co-authorship network of co-authors of Eric Padron

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Padron. A scholar is included among the top collaborators of Eric Padron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Padron. Eric Padron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Jihong, Vijay Suresh Akhade, Joshua Bridgers, et al.. (2025). Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm. Leukemia. 39(4). 917–928.

Jain, Akriti, Somedeb Ball, Onyee Chan, et al.. (2024). Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Annals of Hematology. 103(6). 1941–1945. 5 indexed citations

Xie, Zhuoer, Ling Zhang, Peter Papenhausen, et al.. (2024). Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. SHILAP Revista de lepidopterología. 2(2). 100062–100062.

Komrokji, Rami S., Najla H. Al Ali, Zhuoer Xie, et al.. (2024). IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD). Blood. 144(Supplement 1). 3228–3228.

DeZern, Amy E., Michael Otterstatter, Nancy Gillis, et al.. (2024). Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS). Blood. 144(Supplement 1). 1831–1831.

Zahra, Fatima Tuz, Onyee Chan, Jeffrey E. Lancet, et al.. (2024). Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience. Blood. 144(Supplement 1). 2415–2415. 1 indexed citations

Gillis, Nancy, Eric Padron, Tao Wang, et al.. (2023). Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry. Transplantation and Cellular Therapy. 29(10). 640.e1–640.e8. 4 indexed citations

Komrokji, Rami S., Luis E. Aguirre, Najla H. Al Ali, et al.. (2023). Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Advances. 7(14). 3677–3679. 7 indexed citations

Ferrall‐Fairbanks, Meghan C., Brian Johnson, Christopher T. Letson, et al.. (2022). Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discovery. 3(6). 536–553. 9 indexed citations

10.

Aguirre, Luis E., Akriti Jain, Somedeb Ball, et al.. (2021). Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood. 138(Supplement 1). 1494–1494. 7 indexed citations

11.

Sallman, David A., Hany Elmariah, Kendra Sweet, et al.. (2021). Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes. Blood. 138(Supplement 1). 825–825. 21 indexed citations

12.

Komrokji, Rami S., Najla Al Ali, Onyee Chan, et al.. (2021). Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia & lymphoma. 63(1). 199–204. 2 indexed citations

13.

Belizaire, Roger, Sebastian Koochaki, Namrata D. Udeshi, et al.. (2021). CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Blood. 137(16). 2209–2220. 29 indexed citations

14.

Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2020). Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research. 93. 106367–106367. 13 indexed citations

15.

Badar, Talha, Anikó Szabó, David A. Sallman, et al.. (2020). Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leukemia & lymphoma. 61(6). 1418–1427. 14 indexed citations

16.

Sweet, Kendra, Rami S. Komrokji, Eric Padron, et al.. (2019). Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clinical Cancer Research. 26(1). 54–60. 22 indexed citations

17.

Ferrall‐Fairbanks, Meghan C., Markus Ball, Eric Padron, & Philipp M. Altrock. (2019). Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity. JCO Clinical Cancer Informatics. 3(3). 1–10. 11 indexed citations

18.

Padron, Eric, Amy E. DeZern, Marcio Andrade‐Campos, et al.. (2016). A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Cancer Research. 22(15). 3746–3754. 62 indexed citations

19.

Zeidan, Amer M., Mikkael A. Sekeres, Xiaofeng Wang, et al.. (2015). Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology. 90(11). 1036–1040. 23 indexed citations

20.

Zeidan, Amer M., Mikkael A. Sekeres, Xiaofeng Wang, et al.. (2015). Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. American Journal of Hematology. n/a–n/a. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact